Evaluation of LDL goal achievement in statin consumption, south east of Iran

Malihe Aghasizadeh,Toba Kazemi,Saeede Khosravi Bizhaem,Mahin Baniasadi,Mohammad Reza Khazdair

doi:10.1038/s41598-021-90228-0

Malihe Aghasizadeh, Toba Kazemi + Show 3 more

Open Access

https://doi.org/10.1038/s41598-021-90228-0

Copy DOI

Journal: Scientific Reports	Publication Date: May 24, 2021
Citations: 5	License type: open-access

Affiliation: Birjand University of Medical Sciences

Abstract

Lipid goal achievement and statin consumption were estimated at extreme/very-high/high/moderate and low cardiovascular risk categories. In the cross-sectional study, 585 patients treated with statin therapy referring to the heart clinic of Birjand were recruited. Patients were classified and examined LDL-C values and the proportion reaching targets according to the American Association of Clinical Endocrinologists guideline. Three patterns of statin use (high/moderate/low-intensity statin therapy) in all patients were examined and attainments of LDL-C goal in cardiovascular risk groups have been demonstrated. Over half the populations (57.6%) were in the very-high CVD risk group. The results showed that the proportion of patients meeting total LDL-C goal values according to the guidelines was 43.4%. The frequency of patient had achievement LDL goal lower in high-intensity pattern (N = 13, 2.3%), compared with moderate (N = 496, 86.1%) and low-intensity patterns (N = 67, 11.6%). In general, LDL-C goal achievement was greatest with moderate-intensity statin use. LDL-C reduction after statin consumption was estimated about one-third of the studied population. It seems likely that the achievement of a therapeutic target for serum lipids such as LDL-C improved is far more cost-effective and would be able to reach the target LDL as well changing the type and intensity of statins.

Highlights

Lipid goal achievement and statin consumption were estimated at extreme/very-high/high/moderate and low cardiovascular risk categories
The purpose of this article is to categorize the atherosclerotic cardiovascular diseases (ASCVD) risk level according to Association of Clinical Endocrinologists (AACE) guideline (2017) and estimate percentage of the patient treated with statin derivation for who have achieved the goal of treatment
Precipitations were grouped according to the ASCVD risk level category based on AACE guidelines

Summary

Introduction

Lipid goal achievement and statin consumption were estimated at extreme/very-high/high/moderate and low cardiovascular risk categories. Three patterns of statin use (high/moderate/low-intensity statin therapy) in all patients were examined and attainments of LDL-C goal in cardiovascular risk groups have been demonstrated. Abbreviations ASCVD Atherosclerotic cardiovascular disease CVD Cardiovascular disease DM Diabetes Mellitus LDL-C Low-density lipoprotein cholesterol HMG-CoA 3-Hydroxy-3-methylglutaryl-coenzyme A AACE American Association of Clinical Endocrinologists T2DM Type 2 diabetes mellitus. Over the past few decades, statin derivatives have been used with safely and increasingly clinical advantage in keep away patient from the threat of CVD These groups of inhibitors, by preventing the function of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, play an imperative role in reducing cholesterol and declining the risk of developing atherosclerosis plaques and heart a ttacks[4]. Atorvastatin 10–20 mg Rosuvastatin 5–10 mg Simvastatin 20–40 mg Pravastatin 40–80 mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg twice daily Pitavastatin 2–4 mg

Objectives

Methods

Results

Discussion

Conclusion